Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models

Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University researchers.

New preclinical data presented at the Society for Neuro-Oncology’s Pediatric Conference showed LP-184 extended survival dramatically in mouse models of atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive childhood brain cancer. In one model, median survival soared from 20 to 89 days, which is a 345% improvement, while another saw an increase from 68 to 98 days. The studies also confirmed strong anti-tumor activity across multiple ATRT subtypes and favorable blood-brain barrier penetration, with no apparent toxicity observed in treated animals.

A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.

These results strengthen the scientific foundation for Lantern Pharma Inc. (NASDAQ:LTRN)’s FDA Rare Pediatric Disease Designation for LP-184 in ATRT and pave the way for a planned pediatric clinical trial, expected to launch in late 2025 or early 2026.

LP-184, a next-generation acylfulvene drug, targets tumors with epigenetic dysregulation, such as those with SMARCB1 gene loss, a hallmark of ATRT. With current treatments offering poor outcomes and high toxicity, Lantern Pharma Inc. (NASDAQ:LTRN)’s LP-184’s single-agent efficacy could mark a breakthrough for children facing this devastating diagnosis.

LTRN closed over 9% higher on May 29.

While we acknowledge the potential of LTRN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than LTRN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.